A carregar...
Objective and subjective measures of dalfampridine efficacy in clinical practice
BACKGROUND: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patie...
Na minha lista:
| Publicado no: | Mult Scler J Exp Transl Clin |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6077903/ https://ncbi.nlm.nih.gov/pubmed/30090641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217318786742 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|